Article Text

Download PDFPDF

Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease : a case report
Free
  1. Brigitte Bader-Meunier1,2,
  2. Alice Hadchouel3,
  3. Laureline Berteloot4,
  4. Laura Polivka5,
  5. Vivien Béziat6,7,
  6. Jean-Laurent Casanova1,6,7,8,9,
  7. Romain Lévy1,6,7
  1. 1Pediatric Hematology-Immunology and Rheumatology Unit, Hôpital Necker-Enfants Malades, AP-HP Centre, Paris, France
  2. 2INSERM UMR 1163, Laboratory of Immunogenetics of Paediatric Autoimmunity, Institut Imagine, Paris, France
  3. 3Pediatric Pneumology Unit, Hôpital Necker-Enfants Malades, AP-HP Centre, Paris, France
  4. 4Pediatric Radiology Unit, Hôpital Necker-Enfants Malades, AP-HP Centre, Paris, France
  5. 5Dermatology and Pediatric Dermatology Unit, Hôpital Necker-Enfants Malades, AP-HP Centre, Paris, France
  6. 6Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM UMR 1163, Paris, France
  7. 7Paris Descartes University, Imagine Institute, Paris, France
  8. 8St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
  9. 9Howard Hughes Medical Institute, New York, NY, USA
  1. Correspondence to Dr Brigitte Bader-Meunier, Service d'Immunologie- Hematologie et Rhumatologie Pediatrique, Hopital universitaire Necker-Enfants malades, Paris 75015, France; brigitte.bader-meunier{at}aphp.fr

Statistics from Altmetric.com

We read with interest the report of a series of 61 patients with systemic juvenile idiopathic arthritis (s-JIA) or s-JIA-like associated with high-fatality lung diseases.1 Lung disease was associated with digital clubbing, a high frequency of anaphylactic reactions to tocilizumab, and macrophage activation syndrome (MAS). Because of the low 5-year survival probability of 42%, there is an urgent need to identify efficient drugs to treat such patients. Herein we report the effectiveness and safety of ruxolitinib in one patient demonstrating clinical and radiological characteristics consistent to those reported by Saper et al

A 2-year-old girl born to non-consanguineous parents presented with s-JIA-like since the age of 12 months, including recurring episodes of unexplained fever, urticaria, arthralgia, poor general health status, leukocytosis and elevated serum C-reactive protein (CRP). The use of corticosteroids resulted in a complete remission but the patient relapsed when prednisone was tapered below 0.5 mg/kg/day. Owing to this corticosteroid dependence, the patient received several lines of biological agents from the age 15–22 months, none of which was either effective nor tolerated. Anakinra had no benefit on the patient’s features, and was replaced by canakinumab—but which resulted in a probable drug reaction with eosinophilia and systemic symptoms and a MAS after the third injection. Finally, a third line with tocilizumab led to severe anaphylactic reactions after the second infusion. At age 34 months, the patient developed acute digital clubbing without any respiratory symptoms. Chest CT scan showed a diffuse interstitial disease with interlobular septal thickenings, bronchovascular bundles thickenings, ground glass opacities with a peripheral and lower lobes predominance, and enlargement of mediastinal lymph nodes (figure 1). Bronchoalveolar lavage (BAL) fluid showed 2 50 000 cells /mL (macrophages: 66%, neutrophils: 27%, lymphocytes: 7%). Microbiological investigations were all negative. A whole exome sequencing did not identify any causal mutation.

Figure 1

Radiological response to JAK1/JAK2 blockade with ruxolitininb . (A) Chest CT scan before the initiation of ruxolitinib. (B) Chest CT scan 12 months after the initiation of ruxolitinib.

The expression of interferon (IFN)-stimulated genes in the whole blood of the patient was normal on two occasions, and increased once while the patient received anti-interleukin-1 treatment. Immunophenotyping showed normal counts of T cell, B cell and natural killer (NK) lymphocytes. Further study showed that, among memory CD4+ T cells, the patient had frequencies of Th1 cells well above the control range, and decreased frequencies of Th17 cells (figure 2).

Figure 2

T helper immunophenotyping. (A) Gating strategy in the patient’s peripheral blood mononuclear cells (PBMCs) for T helper immunophenotyping. (B) Representative fluorescence activated cell sorting (FACS) plots are presented. The horizontal bars represent the mean+/-SD. Frequencies of T helper subsets within the CD4+ memory compartment in controls and P. Subsets were defined as follows: Th1 (CXCR5CXCR3+CCR4CCR6), Th2 (CXCR5CXCR3CCR4+CCR6), Th17 (CXCR5CXCR3CCR4+CCR6+) and Tfh (CXCR5+).

At the age of 4, the patient was treated with the Janus kinase 1/2 selective inhibitor ruxolitinib (1 mg/kg/day) in association with oral prednisone (0.5 mg/kg/day) and 3 monthly intravenous infusions of methylprednisolone (600 mg/m2). At last follow-up, 15 months post initiation of ruxolitinib, febrile attacks remitted, CRP value was normal, prednisone was tapered to 0.1 mg/kg/day, and methylprednisolone dosage was progressively decreased to one infusion (300 mg/m2) every 6 weeks. Chest CT scan abnormalities decreased (figure 1). Oxygen saturation increased from 92% to 100%. There was a catch-up growth with an improvement of the height Z-scores from −3 to −2. Ruxolitinib was well tolerated.

Our patient demonstrates features similar to those reported in the series of Saper et al. An upregulation of genes related to the IFNγ reponse both in the (BAL) fluid and lung tissue was demonstrated in some patients from this series.2 In line with a putative pathogenic role of IFNγ signaling, a high frequency of MAS was reported. The observation in our patient of (1) elevated frequency of Th1 cells, main producers of IFNγ3, and (2) a clinical response to ruxolitinib, blocking the IFNγ signalling, although not selectively,4 5 is consistent with this hypothesis. Although no definite conclusion can be drawn from this single case, our report suggests that ruxolitinib may represent a valid therapeutic option to be tested early in patients with s-AJI associated with severe early-onset lung disease.

References

View Abstract

Footnotes

  • Contributors LP and BB-M collected clinical data. VB, J-LC and RL performed the immunological experiments and analysed data. BB-M, LP, AH and LB wrote the paper. AH and LB analysed the pulmonary clinical and radiological data. RL and BB-M supervised the study. All authors have read final approval of the version published.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Parental/guardian consent obtained.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles